시장보고서
상품코드
1229125

두경부편평상피암(HNSCC) 시장 규모와 동향 보고서 : 역학과 파이프라인 분석, 경쟁 평가, 미충족 수요, 임상시험 전략, 예측(2021-2031년)

Head and Neck Squamous Cell Carcinomas (HNSCC) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

발행일: | 리서치사: GlobalData | 페이지 정보: 영문 35 Pages | 배송안내 : 즉시배송


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

두경부편평상피암(HNSCC) 시장에 대해 조사했으며, 질환 개요와 역학, 파이프라인 제품 동향, 미충족 수요와 기회, 시장 전망 등을 제공하고 있습니다.

목차

제1장 서문

제2장 주요 요약

제3장 질환 개요

제4장 시판 약제와 파이프라인 약제 개요

  • 시판약 개요
  • 파이프라인 분석
  • 표적 분석과 임상 벤치마크

제5장 시장 전망

제6장 미충족 수요

제7장 승인 가능성 분석과 단계 이동 성공률 분석

제8장 경쟁력 평가

  • 치료 클래스별 경쟁 분석

제9장 향후 진출 기업

제10장 부록

제11장 문의

KSM 23.03.15

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for Head and Neck Squamous Cell Carcinomas (HNSCC). In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional 7 geographical markets (7M), totaling 15 major markets (15MM). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of GBM, with pricing assumptions based on currently marketed products by class of cell & gene therapies, accompanied by a transparent forecast methodology.

Additionally, the report evaluates indication-specific unmet needs and competitive assessment, and identifies key future players in the cell therapy market.

Cell and gene therapy (CGT) is not an established therapy area in HNSCC, but there is an active clinical pipeline. Gene therapies dominate the HNSCC CGT pipeline with 10 agents in Phase II and 13 agents in Phase I. Autologous T-cell receptors (TCRs) follow close behind with 3 agents in Phase II and 7 agents in Phase I of development. However, CGTs only constitute a modest proportion of the overall HNSCC pipeline, reflecting the unproven efficacy of these modalities in this cancer type.

Cell and gene therapies are expected to capture a combined total of 8% of the HNSCC market by the end of the forecast period in 2031, reaching $262 million in 8MM sales (US, France, Germany, Italy, Spain, UK, Japan, and China).

Sales forecasts for the 7M (Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada) assessed in this analysis show the overall HNSCC market (cell therapies and established/traditional therapies) is expected to reach $163 million by 2031.

CGT agents show promise for partially meeting unmet needs in HNSCC and can provide the most value by producing more therapeutic options for patients with locally advanced HNSCC. CGTs are not expected to address the unmet need of identifying new druggable targets, with the top 5 targets in the HNSCC already being well-established targets.

Key Highlights

Forecast includes 8 countries

Forecast covers 2021-2031

Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Scope

  • This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

  • OBTAIN CELL & GENE THERAPY SALES FORECASTS ACROSS MULTIPLE REGIONS
  • GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES
  • Our indication specific forecast models answer questions such as:
  • What is the target patient pool for cell & gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in eac h market?
  • What is the total market value projected for the forecast end, in 2031?

Table of Contents

Table of Contents

1. Preface

  • 1.1. Contents
  • 1.2. Report Scope

2. Executive Summary

3. Disease Overview

  • 3.1. HNSCC Etiology & Treatment Algorithm 1
  • 3.2. Treatment Algorithm 2

4. Marketed & Pipeline Drugs Overview

  • 4.1. Marketed Drugs Overview
  • 4.2. Pipeline Analysis
  • 4.3. Target Analysis and Clinical Benchmarks

5. Market Outlook

  • 5.1. 10-Year Market Analysis with Drivers and Barriers
  • 5.2. 10-Year Market Outlook - 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

  • 8.1. Competitive Analysis by Class of Therapy

9. Future Players

  • 9.1. Future Players Based on Pipeline Strength

10. Appendix

  • 10.1. Cell and Gene Therapies Forecast Methodology Overview
  • 10.2. Pricing of Cell and Gene Therapies
  • 10.3. Pipeline Launch Assumptions
  • 10.4. Abbreviations
  • 10.5. Methodology
  • 10.6. About the Authors

11. Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제